HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 48.22% | 55.84% | 19.12% | 51.76% | 27.35% |
| Total Depreciation and Amortization | 3.28% | 0.53% | 0.05% | -6.37% | -9.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -191.64% | -82.60% | 94.25% | -61.52% | 0.90% |
| Change in Net Operating Assets | 92.00% | 44,900.00% | -37,050.00% | 52.31% | 547.51% |
| Cash from Operations | 79.71% | 103.03% | 64.96% | 82.77% | 355.40% |
| Capital Expenditure | -- | -153.85% | -- | -- | -950.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -107.55% | -- |
| Cash from Investing | -1,723.81% | -2,330.77% | 81.40% | -108.20% | -950.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -69.55% | -95.67% | -288.69% | -437.82% | -39.90% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -162.78% | 37.81% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -60.45% | -102.26% | 77.19% | -266.86% | -8.08% |
| Foreign Exchange rate Adjustments | -442.86% | 119.61% | -206.67% | 413.68% | 113.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 116.91% | 1,225.00% | 90.82% | -142.69% | 111.08% |